Sanofi’s Latest Asthma Drug Trial Yields Disappointing Results
In a significant setback for Sanofi, the pharmaceutical giant’s next-generation asthma medication, dubbed SNY-123, has failed to meet the efficacy benchmarks during its clinical trials, raising concerns about its potential in an already competitive market. This development has sent ripples through the biotech community, highlighting the uncertainties associated with drug development in the challenging field of respiratory medicine.
Continue reading
The Alarming Reality of Peak Asthma Season: Increased Inhaler Usage and Emissions
As cold weather closes in and the autumn months bring on the peak asthma season, an unexpected consequence emerges: a significant rise in the use of inhalers. This uptick in inhaler usage not only highlights the struggles of asthma sufferers but also casts a spotlight on the environmental impact associated with increased emissions from these medical devices.
Continue reading